Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.52 |
| ▸ | CDK1 | P06493 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 3/20 | 0.36 |
| ▸ | CLK3 | P49761 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039623 | 0.84 | RET (0.73) | RETERBB2CDK1KDRMAP3K8 | |
| Diethylamine SCHEMBL5823126 | 0.83 | RET (0.72) | RETERBB2CDK1KDRMAP3K8 | |
| SCHEMBL4039588 | 0.82 | RET (0.48) | RETERBB2CDK1KDRMAP3K8 | |
| SCHEMBL4039916 | 0.78 | RET (0.54) | RETERBB2CDK1KDRFLT3 | |
| SCHEMBL4042849 | 0.76 | CDK1 (0.58) | RETERBB2CDK1KDRWNT1 | |
| SCHEMBL13797846 | 0.74 | CDK1 (0.63) | RETERBB2CDK1KDRMAP3K8 | |
| SCHEMBL4043674 | 0.74 | RET (0.73) | RETERBB2CDK1KDRMAP3K8 | |
| Diethylamine SCHEMBL5819267 | 0.73 | RET (0.72) | RETERBB2CDK1KDRMAP3K8 | |
| SCHEMBL5819272 | 0.73 | RET (0.55) | RETERBB2CDK1KDRWNT1 | |
| SCHEMBL4035713 | 0.72 | RET (0.75) | RETERBB2CDK1KDRMAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | claimed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | claimed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | RET 222/4885ERBB2 104/4885CDK1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.